Contact Information
Company Information
Company
Oryzon Genomics SA
Annual Revenue
75000000.0
Technologies
Cloudflare DNS
Outlook
Microsoft Office 365
CloudFlare Hosting
Bootstrap Framework
Mobile Friendly
Shutterstock
Google Tag Manager
AI
Keywords
drug discovery & development
biomarker discovery
cancer
neurodegeneration
epigenetics
clinical trials
oryzon
biopharmaceutical
personalized medicine
oncology
cns disorders
lsd1 inhibitors
iadademstat
vafidemstat
therapeutic programs
biomarker identification
target validation
drug development
phase ii
orphan-drug status
hdac inhibitors
genomics
gene expression
medicinal chemistry
functional genomics
neurological diseases
malignant diseases
publicly traded
corporate governance
collaborations
patent portfolio
clinical stage
personalized therapeutics
innovative therapies
biologic drugs
genetic regulation
pharmaceutical research
biopharma
drug candidates
patient-centric
research & development
biotech
medical affairs
phase-specific drugs
investor relations
regulatory pathways
clinical outcomes
healthcare innovation
fda communications
european patent
market strategy
preclinical development
transcriptional regulation
biopharmaceuticals
central nervous system disorders
cancer therapeutics
psychiatric disorders
precision medicine
therapeutic pipeline
proprietary drug candidates
phase ii trials
acute myeloid leukemia
small cell lung cancer
cns diseases
drug commercialization
biotechnology partnerships
healthcare sector
clinical-stage company
epigenetic modulation
therapeutic areas
patient-centric approach
pharmaceutical industry
investment partnerships
health care
health
wellness & fitness
hospital & health care
Get Full Contact Details
Subscribe to reveal email addresses and export contacts.
View Plans